Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

Cited In for PubMed (Select 19162309)

1.

Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model.

Lindenblatt D, Fischer E, Cohrs S, Schibli R, Grünberg J.

EJNMMI Res. 2014 Dec;4(1):54. doi: 10.1186/s13550-014-0054-2. Epub 2014 Oct 3.

2.

Immunotherapeutic approaches to ovarian cancer treatment.

Chester C, Dorigo O, Berek JS, Kohrt H.

J Immunother Cancer. 2015 Mar 24;3:7. doi: 10.1186/s40425-015-0051-7. eCollection 2015. Review.

3.

Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells.

Yu Y, Zhang M, Zhang X, Cai Q, Zhu Z, Jiang W, Xu C.

J Exp Clin Cancer Res. 2014 Sep 28;33:85. doi: 10.1186/s13046-014-0085-6.

4.

Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells.

Yu Y, Zhang M, Zhang X, Cai Q, Hong S, Jiang W, Xu C.

J Hematol Oncol. 2014 May 6;7:39. doi: 10.1186/1756-8722-7-39.

5.

Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.

Correa RJ, Valdes YR, Peart TM, Fazio EN, Bertrand M, McGee J, Préfontaine M, Sugimoto A, DiMattia GE, Shepherd TG.

Carcinogenesis. 2014 Sep;35(9):1951-61. doi: 10.1093/carcin/bgu049. Epub 2014 Feb 22.

PMID:
24562574
6.

Bevacizumab and ovarian cancer.

Garcia A, Singh H.

Ther Adv Med Oncol. 2013 Mar;5(2):133-41. doi: 10.1177/1758834012467661.

7.

High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors.

Sommariva M, de Cesare M, Meini A, Cataldo A, Zaffaroni N, Tagliabue E, Balsari A.

J Transl Med. 2013 Jan 29;11:25. doi: 10.1186/1479-5876-11-25.

8.

Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity.

Gottschalk N, Kimmig R, Lang S, Singh M, Brandau S.

Int J Mol Sci. 2012;13(9):12000-16. doi: 10.3390/ijms130912000. Epub 2012 Sep 20.

9.
10.

Clinical utility of targeted treatments in the management of epithelial ovarian cancer.

Twu C, Han ES.

Biologics. 2012;6:233-44. doi: 10.2147/BTT.S29356. Epub 2012 Jul 26.

11.

Investigational agents in development for the treatment of ovarian cancer.

Westin SN, Herzog TJ, Coleman RL.

Invest New Drugs. 2013 Feb;31(1):213-29. doi: 10.1007/s10637-012-9837-3. Epub 2012 Jun 4. Review.

12.

Targeting angiogenesis in gynecologic cancers.

Zand B, Coleman RL, Sood AK.

Hematol Oncol Clin North Am. 2012 Jun;26(3):543-63, viii. doi: 10.1016/j.hoc.2012.01.009. Review.

13.

A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.

Garcia AA, Sill MW, Lankes HA, Godwin AK, Mannel RS, Armstrong DK, Carolla RL, Liepman MK, Spirtos NM, Fischer EG, Leslie KK.

Gynecol Oncol. 2012 Mar;124(3):569-74. doi: 10.1016/j.ygyno.2011.10.022. Epub 2011 Oct 28.

14.

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.

Mantia-Smaldone GM, Edwards RP, Vlad AM.

Cancer Manag Res. 2011;3:25-38. doi: 10.2147/CMR.S8759. Epub 2010 Dec 30.

15.

Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.

Itamochi H.

World J Biol Chem. 2010 Jul 26;1(7):209-20. doi: 10.4331/wjbc.v1.i7.209.

16.

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.

Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, Liebes L, Chen HX, Muggia FM.

Gynecol Oncol. 2010 Dec;119(3):451-6. doi: 10.1016/j.ygyno.2010.08.008. Epub 2010 Sep 15.

17.

Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.

Wilken JA, Webster KT, Maihle NJ.

J Ovarian Res. 2010 Mar 27;3:7. doi: 10.1186/1757-2215-3-7.

18.

Targeted therapies in epithelial ovarian cancer.

Barrena Medel NI, Wright JD, Herzog TJ.

J Oncol. 2010;2010:314326. doi: 10.1155/2010/314326. Epub 2010 Jan 13.

19.

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ, Calvo K, Choyke P, Kimm D, Steinberg SM, Kohn EC.

Clin Cancer Res. 2010 Jan 15;16(2):664-72. doi: 10.1158/1078-0432.CCR-09-2308. Epub 2010 Jan 12.

20.

Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

Siwak DR, Carey M, Hennessy BT, Nguyen CT, McGahren Murray MJ, Nolden L, Mills GB.

J Oncol. 2010;2010:568938. doi: 10.1155/2010/568938. Epub 2009 Nov 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk